These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10223683)

  • 41. Attenuated bacteria as a DNA delivery vehicle for DNA-mediated immunization.
    Sizemore DR; Branstrom AA; Sadoff JC
    Vaccine; 1997 Jun; 15(8):804-7. PubMed ID: 9234519
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical and laboratory studies of live cytomegalovirus vaccine Ad-169.
    Neff BJ; Weibel RE; Buynak EB; McLean AA; Hilleman MR
    Proc Soc Exp Biol Med; 1979 Jan; 160(1):32-7. PubMed ID: 217022
    [No Abstract]   [Full Text] [Related]  

  • 43. Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus.
    Reap EA; Morris J; Dryga SA; Maughan M; Talarico T; Esch RE; Negri S; Burnett B; Graham A; Olmsted RA; Chulay JD
    Vaccine; 2007 Oct; 25(42):7441-9. PubMed ID: 17870214
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dendritic cell vaccination in allogeneic stem cell recipients: induction of human cytomegalovirus (HCMV)-specific cytotoxic T lymphocyte responses even in patients receiving a transplant from an HCMV-seronegative donor.
    Grigoleit GU; Kapp M; Hebart H; Fick K; Beck R; Jahn G; Einsele H
    J Infect Dis; 2007 Sep; 196(5):699-704. PubMed ID: 17674311
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vaccines for varicella-zoster virus and cytomegalovirus: recent progress.
    Plotkin SA
    Science; 1994 Sep; 265(5177):1383-5. PubMed ID: 8073277
    [No Abstract]   [Full Text] [Related]  

  • 46. Optimization of DNA immunization against human cytomegalovirus.
    Endrész V; Burián K; Berencsi K; Gyulai Z; Kari L; Horton H; Virok D; Méric C; Plotkin SA; Gönczöl E
    Vaccine; 2001 Jul; 19(28-29):3972-80. PubMed ID: 11427273
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero.
    Elek SD; Stern H
    Lancet; 1974 Jan; 1(7845):1-5. PubMed ID: 4128996
    [No Abstract]   [Full Text] [Related]  

  • 48. Natural vs vaccine-acquired immunity to cytomegalovirus.
    Plotkin SA
    JAMA; 2003 Oct; 290(13):1709; author reply 1709. PubMed ID: 14519704
    [No Abstract]   [Full Text] [Related]  

  • 49. Encouraging prospects for immunisation against primary cytomegalovirus infection.
    Griffiths PD; McLean A; Emery VC
    Vaccine; 2001 Jan; 19(11-12):1356-62. PubMed ID: 11163656
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cytomegalovirus: pathogenicity, immunity, and vaccine initiatives.
    Osborn JE
    J Infect Dis; 1981 Apr; 143(4):618-30. PubMed ID: 6263985
    [No Abstract]   [Full Text] [Related]  

  • 51. Letter: Cytomegalovirus infection in utero.
    Plotkin SA
    Lancet; 1974 May; 1(7863):924. PubMed ID: 4133433
    [No Abstract]   [Full Text] [Related]  

  • 52. Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice.
    Britt W; Fay J; Seals J; Kensil C
    J Infect Dis; 1995 Jan; 171(1):18-25. PubMed ID: 7798659
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of temperature-sensitive mutants of mouse cytomegalovirus as vaccines.
    Sandford GR; Burns WH
    J Infect Dis; 1988 Sep; 158(3):596-601. PubMed ID: 2842407
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in Cytomegalovirus-Seronegative Men.
    Adler SP; Manganello AM; Lee R; McVoy MA; Nixon DE; Plotkin S; Mocarski E; Cox JH; Fast PE; Nesterenko PA; Murray SE; Hill AB; Kemble G
    J Infect Dis; 2016 Nov; 214(9):1341-1348. PubMed ID: 27521362
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Perspectives for the control of cytomegalovirus infections in bone marrow transplant recipients.
    Pollard RB; Merigan TC
    Transplant Proc; 1978 Mar; 10(1):241-5. PubMed ID: 205021
    [No Abstract]   [Full Text] [Related]  

  • 56. Human cytomegalovirus vaccine: time to look for alternative options.
    Khanna R; Diamond DJ
    Trends Mol Med; 2006 Jan; 12(1):26-33. PubMed ID: 16337831
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenicity evaluation of DNA vaccines that target guinea pig cytomegalovirus proteins glycoprotein B and UL83.
    Schleiss MR; Bourne N; Jensen NJ; Bravo F; Bernstein DI
    Viral Immunol; 2000; 13(2):155-67. PubMed ID: 10892996
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Editorial: Vaccine against cytomegalovirus.
    Med J Aust; 1974 Mar; 1(13):463-4. PubMed ID: 4364594
    [No Abstract]   [Full Text] [Related]  

  • 59. Prevention of cytomegalovirus disease. Report of a conference.
    Plotkin S
    Pediatr Infect Dis; 1984; 3(1):1-4. PubMed ID: 6322140
    [No Abstract]   [Full Text] [Related]  

  • 60. Progress toward developing a cytomegalovirus vaccine.
    Marshall GS; Plotkin SA
    Infect Dis Clin North Am; 1990 Jun; 4(2):283-98. PubMed ID: 2161034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.